{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:30:55Z","timestamp":1788571855269,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Eva Mayr-Stihl foundation"},{"name":"F\u00f6rderverein Krebsforschung Saar-Pfalz-Mosel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00262-018-2224-y","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T09:23:53Z","timestamp":1534843433000},"page":"1709-1718","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5669-0421","authenticated-orcid":false,"given":"Frank","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Acker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfreundschuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg Thomas","family":"Bittenbring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"issue":"4","key":"2224_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"24","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 24(4):235\u2013242 346(","journal-title":"N Engl J Med"},{"issue":"5","key":"2224_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379\u2013391","journal-title":"Lancet Oncol"},{"issue":"2","key":"2224_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9(2):105\u2013116","journal-title":"Lancet Oncol"},{"issue":"47","key":"2224_CR4","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR (2003) Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22(47): 7359\u20137368","journal-title":"Oncogene"},{"issue":"2","key":"2224_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1053\/j.seminhematol.2010.01.011","volume":"47","author":"GJ Weiner","year":"2010","unstructured":"Weiner GJ (2010) Rituximab: mechanism of action. Semin Hematol 47(2):115\u2013123","journal-title":"Semin Hematol"},{"issue":"4","key":"2224_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","volume":"115","author":"LE Kolk van der","year":"2001","unstructured":"van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH (2001) Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 115(4):807\u2013811","journal-title":"Br J Haematol"},{"issue":"3","key":"2224_CR7","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","volume":"171","author":"N Gaetano Di","year":"2003","unstructured":"Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M, Golay J (2003) Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171(3):1581\u20137","journal-title":"J Immunol"},{"issue":"2","key":"2224_CR8","first-page":"176","volume":"91","author":"J Golay","year":"2006","unstructured":"Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, van Rooijen N, Vago L, Introna M (2006) The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 91(2):176\u2013183","journal-title":"Haematologica"},{"issue":"9","key":"2224_CR9","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1634\/theoncologist.2008-0089","volume":"13","author":"X Zhou","year":"2008","unstructured":"Zhou X, Hu W, Qin X (2008) The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13(9):954\u2013966","journal-title":"Oncologist"},{"issue":"16 Pt 1","key":"2224_CR10","first-page":"5866","volume":"9","author":"FJ Hernandez-Ilizaliturri","year":"2003","unstructured":"Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS (2003) Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin\u2019s lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 9(16 Pt 1):5866\u20135873","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2224_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/01.cji.0000203081.43235.d7","volume":"29","author":"ML Lefebvre","year":"2006","unstructured":"Lefebvre ML, Krause SW, Salcedo M, Nardin A (2006) Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum. J Immunother 29(4):388\u2013397","journal-title":"J Immunother"},{"issue":"13","key":"2224_CR12","doi-asserted-by":"publisher","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","volume":"64","author":"S Dall\u2019Ozzo","year":"2004","unstructured":"Dall\u2019Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G (2004) Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 64(13):4664\u20134669","journal-title":"Cancer Res"},{"issue":"7","key":"2224_CR13","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.4049\/jimmunol.0713732","volume":"182","author":"M Leidi","year":"2009","unstructured":"Leidi M, Gotti E, Bologna L, Miranda E, Rimoldi M, Sica A, Roncalli M, Palumbo GA, Introna M, Golay J (2009) M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. J Immunol 182(7):4415\u20134422","journal-title":"J Immunol"},{"key":"2224_CR14","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fimmu.2013.00076","volume":"4","author":"UJ Seidel","year":"2013","unstructured":"Seidel UJ, Schlegel P, Lang P (2013) Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies. Front Immunol 4:76","journal-title":"Front Immunol"},{"key":"2224_CR15","first-page":"368","volume":"6","author":"W Wang","year":"2015","unstructured":"Wang W, Erbe AK, Hank JA, Morris ZS, Sondel PM (2015) NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol 6:368","journal-title":"Front Immunol"},{"issue":"9","key":"2224_CR16","first-page":"1002","volume":"88","author":"J Golay","year":"2003","unstructured":"Golay J, Manganini M, Facchinetti V, Gramigna R, Broady R, Borleri G, Rambaldi A, Introna M (2003) Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. Haematologica 88(9):1002\u20131012","journal-title":"Haematologica"},{"issue":"17","key":"2224_CR17","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1182\/blood-2011-04-346411","volume":"118","author":"M Ahlgrimm","year":"2011","unstructured":"Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, Bittenbring J (2011) The impact of Fc-gamma receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 118(17):4657\u20134662","journal-title":"Blood"},{"issue":"8","key":"2224_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/intimm\/dxs048","volume":"24","author":"Y Mishima","year":"2012","unstructured":"Mishima Y, Terui Y, Mishima Y, Kuniyoshi R, Matsusaka S, Mikuniya M, Kojima K, Hatake K (2012) High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRllla polymorphism. Int Immunol 24(8):477\u2013483","journal-title":"Int Immunol"},{"issue":"3","key":"2224_CR19","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.chom.2009.08.004","volume":"6","author":"JM Yuk","year":"2009","unstructured":"Yuk JM, Shin DM, Lee HM, Yang CS, Jin HS, Kim KK, Lee ZW, Lee SH, Kim JM, Jo EK (2009) Vitamin D3 induces autophagy in human monocytes\/macrophages via cathelicidin. Cell Host Microbe 6(3):231\u2013243","journal-title":"Cell Host Microbe"},{"issue":"282","key":"2224_CR20","doi-asserted-by":"publisher","first-page":"282ra47","DOI":"10.1126\/scitranslmed.aaa3230","volume":"7","author":"H Bruns","year":"2015","unstructured":"Bruns H, Buttner M, Fabri M, Mougiakakos D, Bittenbring JT, Hoffmann MH, Beier F, Pasemann S, Jitschin R, Hofmann AD, Neumann F, Daniel C et al (2015) Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high-grade B cell lymphoma. Sci Transl Med 7(282):282ra47","journal-title":"Sci Transl Med"},{"issue":"3","key":"2224_CR21","doi-asserted-by":"publisher","first-page":"e58725","DOI":"10.1371\/journal.pone.0058725","volume":"8","author":"A Hossein-nezhad","year":"2013","unstructured":"Hossein-nezhad A, Spira A, Holick MF (2013) Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PLoS One 8(3):e58725","journal-title":"PLoS One"},{"issue":"3","key":"2224_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1056\/NEJMcp1009570","volume":"364","author":"CJ Rosen","year":"2011","unstructured":"Rosen CJ (2011) Clinical practice. Vitamin D insufficiency. N Engl J Med 364(3):248\u2013254","journal-title":"N Engl J Med"},{"issue":"29","key":"2224_CR23","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1200\/JCO.2013.53.4537","volume":"32","author":"JT Bittenbring","year":"2014","unstructured":"Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G, Pfreundschuh M (2014) Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 32(29):3242\u20133248","journal-title":"J Clin Oncol"},{"issue":"13","key":"2224_CR24","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1200\/JCO.2014.57.5092","volume":"33","author":"JL Kelly","year":"2015","unstructured":"Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, Casasnovas O, Maloney DG, Soubeyran P, Rimsza L, Haioun C, Xerri L et al (2015) Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol 33(13):1482\u20131490","journal-title":"J Clin Oncol"},{"issue":"16","key":"2224_CR25","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"20","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 20(16):1659\u20131672 353(","journal-title":"N Engl J Med"},{"issue":"4","key":"2224_CR26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1530\/EJE-09-0932","volume":"162","author":"L Groningen van","year":"2010","unstructured":"van Groningen L, Opdenoordt S, van Sorge A, Telting D, Giesen A, de Boer H (2010) Cholecalciferol loading dose guideline for vitamin D-deficient adults. Eur J Endocrinol 162(4):805\u2013811","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2224_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0022-1759(83)90438-6","volume":"64","author":"C Korzeniewski","year":"1983","unstructured":"Korzeniewski C, Callewaert DM (1983) An enzyme-release assay for natural cytotoxicity. J Immunol Methods 64(3):313\u2013320","journal-title":"J Immunol Methods"},{"issue":"7","key":"2224_CR28","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00198-005-1867-7","volume":"16","author":"B Dawson-Hughes","year":"2005","unstructured":"Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16(7):713\u2013716","journal-title":"Osteoporos Int"},{"key":"2224_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jsbmb.2016.05.017","volume":"163","author":"A Olmos-Ortiz","year":"2016","unstructured":"Olmos-Ortiz A, Garcia-Quiroz J, Lopez-Marure R, Gonzalez-Curiel I, Rivas-Santiago B, Olivares A, Avila E, Barrera D, Halhali A, Caldino F, Larrea F, Diaz L (2016 Oct) Evidence of sexual dimorphism in placental vitamin D metabolism: testosterone inhibits calcitriol-dependent cathelicidin expression. J Steroid Biochem Mol Biol 163:173\u2013182","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2224_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1146\/annurev.pharmtox.44.101802.121453","volume":"44","author":"M Gandhi","year":"2004","unstructured":"Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF (2004) Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 44:499\u2013523","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"2224_CR31","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/j.1349-7006.2007.00455.x","volume":"98","author":"E Suzuki","year":"2007","unstructured":"Suzuki E, Toi M (2007) Improving the efficacy of trastuzumab in breast cancer. Cancer Sci 98(6):767\u2013771","journal-title":"Cancer Sci"},{"issue":"11","key":"2224_CR32","doi-asserted-by":"publisher","first-page":"13013","DOI":"10.18632\/oncotarget.7344","volume":"7","author":"SP Haen","year":"2016","unstructured":"Haen SP, Schmiedel BJ, Rothfelder K, Schmied BJ, Dang TM, Mirza N, Mohle R, Kanz L, Vogel W, Salih HR (2016) Prognostic relevance of HER2\/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab. Oncotarget 7(11):13013\u201313030","journal-title":"Oncotarget"},{"issue":"23","key":"2224_CR33","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1158\/1078-0432.CCR-16-0238","volume":"22","author":"T Caballero-Velazquez","year":"2016","unstructured":"Caballero-Velazquez T, Montero I, Sanchez-Guijo F, Parody R, Saldana R, Valcarcel D, Lopez-Godino O, Ferra IC, Cuesta M, Carrillo-Vico A, Sanchez-Abarca LI, Lopez-Corral L et al (2016) Immunomodulatory Effect of Vitamin D after Allogeneic Stem Cell Transplantation: Results of a Prospective Multicenter Clinical Trial. Clin Cancer Res 22(23):5673\u20135681","journal-title":"Clin Cancer Res"},{"issue":"9824","key":"2224_CR34","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/S0140-6736(11)61650-4","volume":"379","author":"S Manaseki-Holland","year":"2012","unstructured":"Manaseki-Holland S, Maroof Z, Bruce J, Mughal MZ, Masher MI, Bhutta ZA, Walraven G, Chandramohan D (2012) Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial. Lancet 379(9824):1419\u20131427","journal-title":"Lancet"},{"issue":"13","key":"2224_CR35","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jama.2012.12505","volume":"308","author":"DR Murdoch","year":"2012","unstructured":"Murdoch DR, Slow S, Chambers ST, Jennings LC, Stewart AW, Priest PC, Florkowski CM, Livesey JH, Camargo CA, Scragg R (2012) Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial. JAMA 308(13):1333\u20131339","journal-title":"JAMA"},{"issue":"1","key":"2224_CR36","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cam4.1166","volume":"7","author":"S Hohaus","year":"2018","unstructured":"Hohaus S, Tisi MC, Bellesi S, Maiolo E, Alma E, Tartaglia G, Corrente F, Cuccaro A, D\u2019Alo\u2019 F, Basile U, Larocca LM, De S (2018) Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. Cancer Med 7(1):270\u2013281","journal-title":"Cancer Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-018-2224-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2224-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-018-2224-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T19:03:57Z","timestamp":1566327837000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-018-2224-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["2224"],"URL":"https:\/\/doi.org\/10.1007\/s00262-018-2224-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]},"assertion":[{"value":"15 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study had been approved by the local ethical review board (Ethikkommission der \u00c4rztekammer des Saarlandes\u2014No. 178\/17). All procedures performed in this study were in accordance with the ethical standards of this institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The Burkitt lymphoma cell line DAUDI was acquired on March 18, 2015 from the \u201cLeibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures\u201d (Braunschweig, Germany, Invoice 01502841-1) and the breast cancer cell line ZR-75-1 was acquired on May 07, 2014 from \u201cCLS-Cell Lines Service Ltd.\u201d (Eppelheim, Germany, Invoice R140381). Both providers guarantee the authenticity of the respective cell line. Thus, at the time of the study, the two cell lines were not older than 2\u00a0years and were used only in our laboratory. During the study, the authenticity of the lines was ensured by the fact that the antibodies used to induce the ADCC always functioned cell-line-specifically. Moreover, these cell lines are also not included in the list of confirmed misidentified and cross-contaminated cell lines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Cell lines authenticity"}}]}}